Stay updated on Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding lapse notice and Revision: v3.4.1.SummaryDifference0.5%

- Check25 days agoChange DetectedA government funding status notice was added and the page revision tag updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check32 days agoChange DetectedThe page adds a glossary display and updates QC-related metadata, including 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', replacing the older labels 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check46 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. This appears to be a minor version bump and does not alter study content or critical functionality.SummaryDifference0.1%

- Check53 days agoChange DetectedUpdate added in Study Record: last known status and updater (Wilson Miller, Jewish General Hospital) with date 2021-02 and verification status.SummaryDifference0.4%

- Check68 days agoChange DetectedThe page now includes a Locations section with a Quebec site; the Quebec Locations entry and the HHS Vulnerability Disclosure link were removed, and the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic Melanoma: Clinical Trial page.